| Mrs Jenna Therese Belardinelli, OD | |
|
5110 N Blackstone Ave, Fresno, CA 93710-6708 | |
| (559) 221-8900 | |
| Not Available |
| Full Name | Mrs Jenna Therese Belardinelli |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 4 Years |
| Location | 5110 N Blackstone Ave, Fresno, California |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114548153 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 34527 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| 20/20 Optometric Thomas Casagrande Od | 0941270292 | 2 |
News Archive
A promising molecule has offered hope for a new treatment that could stop or slow Parkinson's, something no treatment can currently do.
ICON Central Laboratories - a division of ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries - today announced the opening of a new laboratory facility in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD). It is the third ICON laboratory in the Asia-Pacific region.
Most cancers are caused by a large variety of factors that vary from one person to another. To unravel this complexity, genes that contribute to the development of a respective cancer must be identified. Such genes are called oncogenes. A good example of an oncogene is CDK8: Cyclin-dependent kinase 8.
Oxis International, Inc., a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015.
› Verified 3 days ago
| Provider Name | 20/20 Optometric Thomas Casagrande Od |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1801081377 PECOS PAC ID: 0941270292 Enrollment ID: O20040726001443 |
News Archive
A promising molecule has offered hope for a new treatment that could stop or slow Parkinson's, something no treatment can currently do.
ICON Central Laboratories - a division of ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries - today announced the opening of a new laboratory facility in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD). It is the third ICON laboratory in the Asia-Pacific region.
Most cancers are caused by a large variety of factors that vary from one person to another. To unravel this complexity, genes that contribute to the development of a respective cancer must be identified. Such genes are called oncogenes. A good example of an oncogene is CDK8: Cyclin-dependent kinase 8.
Oxis International, Inc., a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jenna Therese Belardinelli, OD 5110 N Blackstone Ave Ste 108, Fresno, CA 93710-6708 Ph: (559) 221-8900 | Mrs Jenna Therese Belardinelli, OD 5110 N Blackstone Ave, Fresno, CA 93710-6708 Ph: (559) 221-8900 |
News Archive
A promising molecule has offered hope for a new treatment that could stop or slow Parkinson's, something no treatment can currently do.
ICON Central Laboratories - a division of ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries - today announced the opening of a new laboratory facility in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD). It is the third ICON laboratory in the Asia-Pacific region.
Most cancers are caused by a large variety of factors that vary from one person to another. To unravel this complexity, genes that contribute to the development of a respective cancer must be identified. Such genes are called oncogenes. A good example of an oncogene is CDK8: Cyclin-dependent kinase 8.
Oxis International, Inc., a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015.
› Verified 3 days ago
Dr. Scott Randall Hultman, O,D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3636 N Blackstone Ave, Fresno, CA 93726 Phone: 559-244-3319 | |
Dr. Thomas Pearson, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1360 E Herndon Ave, Suite 401, Fresno, CA 93720 Phone: 559-449-5010 Fax: 559-449-5014 | |
Eye-q Vision Care Optometrist Medicare: Not Enrolled in Medicare Practice Location: 7075 N Sharon Ave, Fresno, CA 93720 Phone: 559-486-2000 | |
Dr. Andrea Cristina Huerta, OD Optometrist Medicare: Medicare Enrolled Practice Location: 7075 N Sharon Ave, Fresno, CA 93720 Phone: 559-389-5723 Fax: 559-256-8595 | |
Dr. David R Urien, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5430 N Palm Ave, Suite 101, Fresno, CA 93704 Phone: 559-432-0606 Fax: 559-432-0608 | |
Dr. Steven W. Shute, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 7075 N Sharon Ave, Fresno, CA 93720 Phone: 559-486-2000 | |
Dr. Elmer Wong, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6700 N 1st St, 103, Fresno, CA 93710 Phone: 559-438-6440 Fax: 559-438-4324 |